NCT00622388 2015-07-24Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After TransplantGlaxoSmithKlinePhase 2 Completed81 enrolled 18 charts
NCT00823719 2013-03-12Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)GlaxoSmithKlinePhase 2 Completed61 enrolled 25 charts